Frontier Medicines completed a $67 million round of A financing

$67 million round of financing for frontier Pharmaceuticals, a biopharmaceutical company, on June 25, local time. This round of financing will be used to support the company's development of a variety of protein target drugs.It is reported that the current round of financing by Dearfield, DROIA Oncology Ventures, MPM Capital, RA Capital Management and other investment.Founded in 2018 and headquartered in California, Frontier Pharmaceuticals is a clinical biopharmaceutical company. So far, about 90 percent of human proteins cannot be targeted for binding by small molecule drugs, because there are no known binding points on the protein surface, so most drugs cannot enter human cells to treat diseases through protein action. However, Frontier Medicines believes that as proteins move, they bend and form temporary targets with which the drug can bind. Using chemical proteomics techniques, Frontier Pharmaceuticals has found that these temporary targets can span multiple human cell membranes and can be combined with drugs to treat diseases. This allows for the treatment of multiple viral proteins through human intervention, which were previously considered "indesaventable" in the medical community, making it possible to cure a variety of difficult diseases. Daniel K. Nomura, co-founder of Frontier Pharmaceuticals, said: "Our platform covers most of the human protein database, including proteins that the traditional medical community considers not to be a target for drugs. We will use computer technology to expand the pool of co-priced compounds and develop new protein degradation methods as soon as possible to treat cancers that have not yet been solved. The company's platform will provide data support for our research and development of protein therapy technologies. The
About , founded in 1994 in New York, USA, is an investment management company dedicated to the development of the healthcare industry through investment. The company manages more than $8 billion and has completed 79 investments so far.
About DROIA Oncology Ventures DROIA Oncology Ventures, founded in 2011 and headquartered in Luxembourg, is a venture capital firm focused on investing in cancer treatment start-ups that have completed eight investments.
About MPM Capital MPM Capital, founded in 1996 and headquartered in Massachusetts, USA, is a venture capital firm focused on providing development funds to early and late-stage companies, focusing primarily on healthcare, and has completed 203 investments. In addition to providing financial support to businesses, MPM Capital provides a team of professionals to help companies develop relevant technologies and manage companies scientifically.
About RA Capital Management/span> RA Capital Management Founded in 2001 and headquartered in Massachusetts, USA, is a venture capital firm focused on investing in the early and late stages of life sciences and drug development, and has completed 111 investments. (arterial
)